



CERTIFICATE OF MAILING  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

December 21, 2004

Date

  
Shelley P.M. Fussey

1642  
  
**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Thorpe and Ran

Serial No.: 09/998,833

Filed: November 30, 2001

For: COMBINED CANCER TREATMENT  
METHODS USING ANTIBODIES TO  
AMINOPHOSPHOLIPIDS

Group Art Unit: 1642

Examiner: Fetterolf

Atty. Dkt. No.: 4001.002299

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A first Official Action reflecting examination on the merits has been received in the present application. However, this Supplemental Information Disclosure Statement is being filed prior to the mailing of a final Official Action, notice of allowance or an Action that closes prosecution, and is timely filed in accordance with 37 C.F.R. § 1.97(c) without a fee in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a foreign counterpart to the present application. The listed documents were provided by European legal representatives of another party in connection with their defense to an Opposition filed against their European patent by the licensee of the present application. The listed documents were provided by the other party with a letter dated September 21, 2004, which was sent to European legal representatives of the licensee of the present application on September 23, 2004. The present statement is being filed within three months of the date of the original letter and is thus timely.

No fees are due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002299.

Respectfully submitted,  
Williams, Morgan & Amerson, P.C.  
Customer No. 23720

  
Shelley P.M. Fussey, Ph.D.  
Reg. No. 39,458  
Agent for Applicants

10333 Richmond, Suite 1100  
Houston, Texas, 77042  
(713) 934-4079  
Date: December 21, 2004

Form PTO-1449 (modified)

Atty. Docket No.  
4001.002299Serial No.  
09/998,833

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
November 30, 2001Group:  
1642U.S. Patent Documents  
*See Page*Foreign Patent Documents  
*See Page*Other Art  
*See Page 1*

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C118	Bicknell and Harris, "Anticancer Strategies Involving the Vasculature: Vascular Targeting and the Inhibition of Angiogenesis," <i>Seminars in Cancer Biology</i> , 3:399-407, 1992.
	C119	Bicknell and Harris, "Novel Growth Regulatory Factors and Tumour Angiogenesis," <i>Eur. J. Cancer</i> , 27(6):781-785, 1991.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.